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False-Negative Sentinel Node Biopsy
Omgo E. Nieweg, MD, PhD
Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, the Netherlands
The concept of the orderly progression of lymph node
metastases is exciting and appeals to the surgical frame of
mind. The momentum of the practice of lymphatic map-
ping may cause people to get carried away by their
enthusiasm. It is thus important to keep an open eye for
developments that may not live up to the expectations, and
therefore, the paper from the Italian Melanoma Intergroup
in this issue deserves attention. An important purpose of
the study of 1313 patients with melanoma was to determine
the ability of sentinel node biopsy to identify involved
lymph node basins. The false-negative rate was found to be
14.4%; this high rate was obtained despite a meticulous
technique and a comprehensive quality control program.
1
High false-negative rates have been reported before but
have rarely caused a stir.
For patients with melanoma, there has long been con-
sensus on the principal aspects of the technique of
lymphatic mapping. The combination of preoperative
lymphoscintigraphy and intraoperative use of both blue dye
and a gamma ray detection probe provides the best retrieval
rate. The sentinel node is identiﬁed in close to 100% of
patients. The morbidity of the procedure is limited. The
tumor status of the sentinel node has proven to be the most
important prognostic factor and has been incorporated in
the staging system.
2 There is initial evidence that mela-
noma patients with lymph node metastases have an
improved chance of survival if regional node dissection is
done early on the basis of sentinel node status.
3
Morton and Cochran, who introduced sentinel node
biopsy, initially performed the procedure with routine
regional node dissection for conﬁrmation and found an
encouraging false-negative rate of 5%.
4 Conﬁrmatory
lymph node dissection was quickly abolished, and the
false-negative cases were subsequently identiﬁed through
observation of recurrences in the lymph node basin after a
tumor-free sentinel node had been removed. Initially, many
investigators looked favorably on the reliability of lym-
phatic mapping to detect nodal metastases, but the follow-
up duration was too short for all recurrences to manifest.
Also, many investigators calculated the rate of false-neg-
ative procedures over the entire group of patients or over
the group of sentinel node–negative patients.
5 This is not
correct because one cannot miss an involved node in a
patient who does not have involved nodes. Because only
approximately 20% of the patients have lymph node
metastases, this questionable way of calculating decreases
the false-negative rate by a factor of 5. Testori et al. cor-
rectly point out that the false-negative rate should be
deﬁned as the fraction of the patients with involved nodes
that is missed by the procedure and becomes evident later
on when the nodes become clinically detectable (Table 1).
The false-negative rate is the counterpart of the sensitivity,
which is deﬁned as the proportion of node-positive patients
(sentinel node–positive patients and patients with recurring
disease) that is identiﬁed by sentinel node biopsy. Early
publications from reputable institutions and cooperative
groups around the world showed false-negative rates
ranging from 16% to 38% when recalculated to comply
with the above recommended deﬁnition.
5 Even in the
interim analysis of the Multicenter Selective Lymphade-
nectomy Trial I, the false-negative rate is 17.6%.
3
These high false-negative rates are reason for concern
and reﬂection. What may be the cause? Testori et al.
mention the nuclear medicine physician, the surgeon, and
the pathologist as sources of failure, but there are more. It
may be that the concept of sequential dissemination does
not always apply. We are dealing with a biological system
with associated variability. It is conceivable that tumor
cells may pass through a sentinel node and lodge in the
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scintigraphy is not 100% accurate in pointing out the
sentinel node. The new and sensitive single-photon emis-
sion computed tomography/computed tomography method
has demonstrated that there are more sentinel nodes
than can be found via conventional lymphoscintigraphy.
6
Lymph ﬂow is known to be variable. It is possible that the
sentinel node contains tumor that blocks the lymphatic
channel.
7 Scintigraphy and blue dye will then be diverted
to a ‘‘neo’’ sentinel node that may not yet be involved. We
know how fast lymph ﬂuid travels through a lymph vessel,
but little is know about the kinetics of melanoma cells in
lymphatics. Thus, another reason for a false-negative result
may be that tumor cells are still in transit at the time of the
sentinel node biopsy.
A meta-analysis of published results of lymphatic map-
ping in breast cancer patients revealed that the false-
negative rate ranges between 0% and 3% in that disease,
with a weighed combined sensitivity of 100%.
8 An inter-
esting question is why the sensitivity is so much better in
breast cancer. Lymphatic mapping started later in breast
cancer, and completion node dissection was performed for a
longer period of time than in melanoma. As a result, there
are relatively few breast cancer studies with a long duration
of follow-up. The median follow-up in the above-men-
tioned meta-analysis was 34 months.
8 Differences in the
physiology of lymph ﬂow may also explain part of the
disparity in the false-negative rate. Lymph ﬂow from the
skin is more variable compared with drainage from the
breast parenchyma. We know this from studies where
lymphoscintigraphy was performed twice in the same
patient and a different sentinel node was visualized in 10%
to 15% of the melanoma patients, but in none of the breast
cancer patients.
9,10 This suggests that in a fair number of
melanoma patients, not all sentinel nodes are collected.
Preoperative ultrasonography was introduced to identify
metastases that may not be palpable but are large enough to
block the inﬂow of lymph ﬂuid.
7,11 Ultrasound may thus
identify the very nodes that will fail to pick up the tracers
and may pass unnoticed during lymphatic mapping, causing
the false-negative results later on. Ultrasound proved to be a
valuable to detect nonpalpable metastases in patients with
breast cancer. Radiologists note that ultrasound is more
difﬁcult in melanoma—and indeed, the radiologists at my
institution, who are so apt at ﬁnding lymph node metastases
in breast cancer patients (sensitivity 21%), fail dramatically
when the disease is melanoma (sensitivity 4.7%).
Differences in the biology of the two diseases may play a
role as well. Breast cancer is often a more slowly growing
disease, which means that it will take more time for
recurrence to manifest. The median time to recurrence in
the axilla has been reported to be more than 6 years.
12 In
melanoma, 80% of the recurrences have established them-
selves within 3 years.
13 Breast cancer cells in lymph nodes
more often cluster together, which makes them easier to
spot by the pathologist. The smaller melanoma tumor
clumps may also metastasize via lymphatic channels with a
smaller diameter. Therefore, one may speculate that they
can spread to additional lymph nodes via narrow collateral
lymphatic vessels that may not be open all the time and may
not be depicted on the lymphoscintigram. In breast cancer,
the procedure is more forgiving for a number of reasons.
Several retrospective and prospective studies suggest that
only about a third of the breast cancer metastases in the
axilla develop into clinically important disease. Data from
the Multicenter Selective Lymphadenectomy Trial suggest
that this percentage appears to be considerably higher in
melanoma.
3 The radiotherapy to the breast that is part of
breast-conserving treatment is likely to clean up some of the
involved nodes that surgeons overlook and leave behind in
the adjacent axilla. The same can be said for the adjuvant
systemic treatment that many of these patients receive.
A few changes have been made in the technique since its
introduction. For instance, intraoperative palpation of the
lymph node ﬁeld was introduced to identify unstained,
nonradioactive nodes that are suspicious because of their
consistency or size.
Some recent studies with a follow-up duration exceed-
ing 3 years show improved false-negative rates of
approximately 10%.
14–19
Howmanyrecurrencesareacceptable?Inmelanoma,this
question is more pressing than in breast cancer because the
sentinelnodeprocedureisanadditionaloperation,compared
with the preexisting situation in which clinically normal
lymph node ﬁelds were generally observed. Most melano-
mologiststhinkthattheextraprognosticinformationandthe
recently established survival beneﬁt in node-positive
patients outweigh the limited morbidity and the substantial
false-negative rate. Single-photon emission computed
tomography/computed tomography and ultrasound may
TABLE 1 Deﬁnition of terms
SLN sentinel lymph node
false-negative rate ¼f patients with negative SLN with recurrent diseaseg=
fpatients with negative SLN with recurrent disease þ patients with positive SLNg
sensitivity ¼f patients with positive SLNg=
fpatients with negative SLN with recurrent disease þ patients with positive SLNg
2090 O. E. Nieweglower the false-negative rate in the future, but the variability
of lymph drainage from the skin and the pathophysiology of
the disease are factors that will hamper further reduction.
REFERENCES
1. Testori A, De Salvo GL, Montesco MC, et al. Clinical consid-
erations on sentinel node biopsy in melanoma from an Italian
multicentric study on 1313 patients (SOLISM-IMI). Ann Surg
Oncol. (in press) DOI:10.1245/s10434-008-0273-8.
2. Gershenwald JE, Thompson W, Mansﬁeld PF, et al. Multi-insti-
tutional melanoma lymphatic mapping experience: the prognostic
value of sentinel lymph node status in 612 stage I or II melanoma
patients. J Clin Oncol. 1999;17:976–83.
3. Morton DL, Thompson JF, Essner R, et al. Immediate versus
delayed lymphadectomy in the management of primary mela-
noma. N Engl J Med. 2006;355:1307–17.
4. Morton DL, Wen D-R, Wong JH, et al. Technical details of
intraoperative lymphatic mapping for early stage melanoma. Arch
Surg. 1992;127:392–9.
5. Nieweg OE, Tanis PJ, De Vries JDH, Kroon BBR. Sensitivity of
sentinel node biopsy in melanoma. J Surg Oncol. 2001;78:223–4.
6. Van der Ploeg IMC, Valde ´s Olmos RA, Nieweg OE, et al. The
additional value of SPECT/CT in lymphatic mapping in breast
cancer and melanoma. J Nucl Med. 2007;48:1756–60.
7. Leijte JAP, Van der Ploeg IMC, Valde ´s Olmos RA, Nieweg OE,
Horenblas S. Visualization of tumor-blockage and rerouting of
lymphatic drainage in penile cancer patients using SPECT/CT.
J Nucl Med. (in press).
8. Van der Ploeg IMC, Nieweg OE, Van Rijk MC, Valde ´s Olmos
RA, Kroon BBR. Axillary recurrence after a tumour-negative
sentinel node biopsy in breast cancer patients: a systematic
review and meta-analysis of the literature. Eur J Surg Oncol.
2008;34:1277–84.
9. Kapteijn BAE, Nieweg OE, Valde ´s Olmos RA, et al. Repro-
ducibility of lymphoscintigraphy for lymphatic mapping in
patients with cutaneous melanoma. J Nucl Med. 1996;37:972–5.
10. Tanis PJ, Valde ´s Olmos RA, Muller SH, Nieweg OE. Lymphatic
mapping in patients with breast carcinoma: reproducibility of
lymphoscintigraphic results. Radiology. 2003;228:546–51.
11. De Kanter AY, Van Geel AN, Paul MA, et al. Controlled intro-
duction of the sentinel node biopsy in breast cancer in a multi-
centre setting: the role of a coordinator for quality control. Eur J
Surg Oncol. 2000;26:652–6.
12. Wright FC, Walker J, Law CH, McCready DR. Outcomes after
localized axillary node recurrence in breast cancer. Ann Surg
Oncol. 2003;10:1054–8.
13. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence
analysis of 840 cutaneous melanomas: a proposal for a follow-up
schedule. Tumori. 1994;80:188–97.
14. Doting MH, Hoekstra HJ, Plukker JT, et al. Is sentinel node
biopsy beneﬁcial in melanoma patients? A report on 200 patients
with cutaneous melanoma. Eur J Surg Oncol. 2003;28:673–8.
15. Vuylsteke RJ, van Leeuwen PA, Muller MG, et al. Clinical
outcome of stage I/II melanoma patients after selective sentinel
lymph node dissection: long-term follow-up results. J Clin Oncol.
2003;21:1057–65.
16. Estourgie SH, Nieweg OE, Valde ´s Olmos RA, Hoefnagel CA,
Kroon BBR. Review and evaluation of sentinel node procedures
in 250 melanoma patients with a median follow-up of 6 years.
Ann Surg Oncol. 2003;10:681–8.
17. Fincher TR, McCarty TM, Fisher TL, et al. Patterns of recurrence
after sentinel lymph node biopsy for cutaneous melanoma. Am J
Surg. 2003;186:675–81.
18. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846
cutaneous melanoma patients from a single center after a negative
sentinel node biopsy. Ann Surg Oncol. 2005;12:429–39.
19. Zogakis TG, Essner R, Wang HJ, et al. Melanoma recurrence
patterns after negative sentinel lymphadenectomy. Arch Surg.
2005;140:865–71.
False-Negative Sentinel Node Biopsy 2091